Tessa Gargett
Tessa Gargett
Centre for Cancer Biology, University of South Australia
Verified email at sa.gov.au
Cited by
Cited by
The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
T Gargett, MP Brown
Frontiers in pharmacology 5, 235, 2014
GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade
T Gargett, W Yu, G Dotti, ES Yvon, SN Christo, JD Hayball, ID Lewis, ...
Molecular Therapy 24 (6), 1135-1149, 2016
Genome-wide identification of human FOXP3 target genes in natural regulatory T cells
TJ Sadlon, BG Wilkinson, S Pederson, CY Brown, S Bresatz, T Gargett, ...
The Journal of Immunology 185 (2), 1071-1081, 2010
Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
T Gargett, MP Brown
Cytotherapy 17 (4), 487-495, 2015
Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells
JF Hutton, T Gargett, TJ Sadlon, S Bresatz, CY Brown, H Zola, ...
Journal of leukocyte biology 85 (3), 445-451, 2009
Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector
CY Brown, T Sadlon, T Gargett, E Melville, R Zhang, Y Drabsch, M Ling, ...
Human gene therapy 21 (8), 1005-1017, 2010
BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro
T Gargett, CK Fraser, G Dotti, ES Yvon, MP Brown
Journal of immunotherapy 38 (1), 12-23, 2015
Induction of antigen‐positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response
T Gargett, B Grubor‐Bauk, TJ Garrod, W Yu, D Miller, L Major, ...
Immunology and cell biology 92 (4), 359-367, 2014
Increase in DNA vaccine efficacy by virosome delivery and co‐expression of a cytolytic protein
T Gargett, B Grubor‐Bauk, D Miller, T Garrod, S Yu, S Wesselingh, ...
Clinical & translational immunology 3 (6), e18, 2014
GM‐CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid‐derived suppressor cells in vitro
T Gargett, SN Christo, TR Hercus, N Abbas, N Singhal, AF Lopez, ...
Clinical & translational immunology 5 (12), e119, 2016
DNA vaccines encoding membrane‐bound or secreted forms of heat shock protein 70 exhibit improved potency
TJ Garrod, B Grubor‐Bauk, T Gargett, Y Li, DS Miller, W Yu, L Major, ...
European journal of immunology 44 (7), 1992-2002, 2014
Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma
T Gargett, MN Abbas, P Rolan, JD Price, KM Gosling, A Ferrante, ...
Cancer Immunology, Immunotherapy 67 (9), 1461-1472, 2018
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
MP Brown, LM Ebert, T Gargett
Clinical & translational immunology 8 (5), e1050, 2019
A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice
W Yu, B Grubor-Bauk, T Gargett, T Garrod, EJ Gowans
Vaccine 32 (27), 3409-3416, 2014
Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency
T Garrod, B Grubor-Bauk, S Yu, T Gargett, EJ Gowans
Human vaccines & immunotherapeutics 10 (9), 2679-2683, 2014
Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology
LM Ebert, W Yu, T Gargett, MP Brown
Biochemical society transactions 46 (2), 391-401, 2018
Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag
TJ Garrod, T Gargett, W Yu, L Major, CJ Burrell, S Wesselingh, A Suhrbier, ...
Virus research 192, 25-33, 2014
Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype
T Gargett, N Truong, LM Ebert, W Yu, MP Brown
Cytotherapy 21 (6), 593-602, 2019
Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells
P Zhang, J Raju, MA Ullah, R Au, A Varelias, KH Gartlan, SD Olver, ...
Clinical Cancer Research 25 (6), 1749-1755, 2019
Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma
J Mencel, T Gargett, N Karanth, A Pokorny, MP Brown, M Charakidis
Asia‐Pacific Journal of Clinical Oncology 15 (6), 383-386, 2019
The system can't perform the operation now. Try again later.
Articles 1–20